FENNEC PHARMACEUTICALS INC.: 10-Q filed 2016-08-12
What FENNEC PHARMACEUTICALS INC. reported in its quarterly report filed 2016-08-12 (fiscal Q2 2016): 23 published measures, 85 facts as tagged in accession 0001144204-16-118605.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-08-12
- Fiscal period
- fiscal Q2 2016
- Accession
- 0001144204-16-118605 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All FENNEC PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 5,104,000 | USD | |
| At 2015-12-31 | 1,019,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 451,000 | USD | |
| At 2015-12-31 | 471,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 4,653,000 | USD | |
| At 2016-03-31 | 243,000 | USD | |
| At 2015-12-31 | 548,000 | USD | |
| At 2015-09-30 | 1,019,000 | USD | |
| At 2015-06-30 | 1,112,000 | USD | |
| At 2015-03-31 | 826,000 | USD | |
| At 2014-12-31 | 613,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 5,081,000 | USD | |
| At 2016-03-31 | 545,000 | USD | |
| At 2015-12-31 | 942,000 | USD | |
| At 2015-06-30 | 1,854,000 | USD | |
| At 2015-03-31 | 1,916,000 | USD | |
| At 2014-12-31 | 2,307,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -724,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -1,144,000 | USD | 182 |
| 2016-01-01 to 2016-03-31 | -420,000 | USD | 91 |
| 2015-10-01 to 2015-12-31 | -540,000 | USD | 92 |
| 2015-07-01 to 2015-09-30 | -123,000 | USD | 92 |
| 2015-04-01 to 2015-06-30 | -173,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 4,000 | USD | 181 |
| 2015-01-01 to 2015-03-31 | 177,000 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 0 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 0 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 0 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 0 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | -112,677,000 | USD | |
| At 2015-12-31 | -111,533,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 12,813,000 | shares | 91 |
| 2016-01-01 to 2016-06-30 | 11,873,000 | shares | 182 |
| 2015-04-01 to 2015-06-30 | 10,830,000 | shares | 91 |
| 2015-01-01 to 2015-06-30 | 10,718,000 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 12,813,000 | shares | 91 |
| 2016-01-01 to 2016-06-30 | 11,873,000 | shares | 182 |
| 2015-04-01 to 2015-06-30 | 10,830,000 | shares | 91 |
| 2015-01-01 to 2015-06-30 | 12,953,000 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -0.06 | USD/shares | 91 |
| 2016-01-01 to 2016-06-30 | -0.1 | USD/shares | 182 |
| 2015-04-01 to 2015-06-30 | -0.02 | USD/shares | 91 |
| 2015-01-01 to 2015-06-30 | 0 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -0.06 | USD/shares | 91 |
| 2016-01-01 to 2016-06-30 | -0.1 | USD/shares | 182 |
| 2015-04-01 to 2015-06-30 | -0.02 | USD/shares | 91 |
| 2015-01-01 to 2015-06-30 | 0 | USD/shares | 181 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 111,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 111,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 10,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 19,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -707,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -1,161,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -549,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -1,001,000 | USD | 181 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 451,000 | USD | |
| At 2015-12-31 | 471,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 345,000 | USD | |
| At 2015-12-31 | 297,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 139,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 186,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 54,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 97,000 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 13,643,000 | shares | |
| At 2015-12-31 | 10,920,000 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 1,243,000 | USD | |
| At 2015-12-31 | 1,243,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 50,000 | USD | |
| At 2015-12-31 | 92,000 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 568,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 975,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 495,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 904,000 | USD | 181 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -3,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | -12,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | -10,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | -7,000 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -17,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 17,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 376,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 1,005,000 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 120,000 | USD | 91 |
| 2016-01-01 to 2016-06-30 | 48,000 | USD | 182 |
| 2015-04-01 to 2015-06-30 | 17,000 | USD | 91 |
| 2015-01-01 to 2015-06-30 | 93,000 | USD | 181 |
Inspect the source
- Entity
- FENNEC PHARMACEUTICALS INC. / CIK 0001211583
- Captured
- 2026-09-19T11:17:02.352Z
- SEC response SHA-256
f5de26e280e9814def3db187bfe6961cb26c6e601a5f986375859c81818e8ab8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001211583.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))